Head-to-head evidence
Eslicarbazepine acetate vs Oxcarbazepine (Trileptal)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: Voltage-gated sodium channel · full Epilepsy pipeline
Eslicarbazepine acetate · Aptiom
Marketed by Sumitomo Pharma and partners
NCT00957684 · Phase 3 · completed
The main study was randomized, quadruple-blind, placebo-controlled, and included 402 participants, with seizure frequency as a clinical primary endpoint. Although seizure frequency was lower in all eslicarbazepine groups than with placebo, the posted registry data do not state whether the prespecified primary comparison was statistically significant, so the result remains unclear.
Oxcarbazepine (Trileptal)
Marketed by Novartis
NCT00050934 · Phase 3 · completed
The study enrolled 132 participants and measured the clinical outcome of seizure-frequency change, but the registry does not document randomization, blinding, or a comparator arm. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Eslicarbazepine acetate's landscape · Oxcarbazepine (Trileptal)'s landscape